عرض بسيط للتسجيلة

المؤلفFuruya-Kanamori, Luis
المؤلفDoi, Suhail Ar
المؤلفOnitilo, Adedayo
المؤلفAkhtar, Saghir
تاريخ الإتاحة2019-12-15T06:29:01Z
تاريخ النشر2019-11-01
اسم المنشورExpert Opinion on Drug Safety
المعرّفhttp://dx.doi.org/10.1080/14740338.2020.1691167
الاقتباسLuis Furuya-Kanamori, Suhail Ar Doi, Adedayo Onitilo & Saghir Akhtar (2019) Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?, Expert Opinion on Drug Safety, DOI: 10.1080/14740338.2020.1691167
الرقم المعياري الدولي للكتاب1474-0338
معرّف المصادر الموحدhttp://hdl.handle.net/10576/12398
الملخصRecent studies have shown an increase risk of cardiovascular and hematological adverse events associated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs). The authors hypothesize that the original studies may have produced exaggerated results because of the small baseline risks involved.: A meta-analysis that included 71 trials, 8 different VEGFR-TKIs, and 11 adverse events was re-analyzed. The outcome of interest was re-defined as the complementary outcome (i.e. remaining free of an adverse event). The inverse variance heterogeneity model was used to pool the effect size.: VEGFR-TKIs decreased the risk of remaining free of hypertension by 7% (RR 0.93; 95%CI:0.88-0.97). Specific VEGFR-TKIs; pazopanib, regorafenib, and nintedanib were associated with a decrease risk of remaining free of an arterial thrombotic event (RR 0.96; 95%CI:0.93-0.99), thrombocytopenia (RR 0.91; 95%CI:0.89-0.93), and bleeding (RR 0.96; 95%CI:0.93-0.99) respectively. VEGFR-TKIs were not associated with thrombotic event, myocardial infarction, stroke, venous thrombotic event, pulmonary embolism, left ventricular dysfunction, or QTc interval prolongation.: VEGFR-TKIs are associated with a small increase in risk of patients developing hypertension, arterial thrombotic events, thrombocytopenia, and bleeding. Previous studies overestimated the actual risk associated with VEGFR-TKIs by analyzing the outcome with the lower baseline risk.
اللغةen
الناشرTaylor & Francis
الموضوعadverse events
cardiovascular events
meta-analysis
risk
tyrosine kinase inhibitors
العنوانIs there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
النوعArticle
ESSN1744-764X
dc.accessType Abstract Only


الملفات في هذه التسجيلة

الملفاتالحجمالصيغةالعرض

لا توجد ملفات لها صلة بهذه التسجيلة.

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة